Antibiotics in Burn Care: Indications, Limitations and Evidence

Authors: Dr. Bettaswamy H V[1], Dr. Nimmagadda Venkat Rao[2], Dr. Hanumanthachar Joshi[3]

Affiliations:

[1] Assistant Professor, Department of Pharmacy Practice, Sarada Vilas College of Pharmacy, Mysuru, India

[2] Head of Department, Department of Pharmacology, Sarada Vilas College of Pharmacy, Mysuru, India

[3] Principal, Sarada Vilas College of Pharmacy, Mysuru, India

Corresponding Author:

Dr. Betta swamy H V

Assistant Professor

Department of Pharmacy Practice

Sarada Vilas College of Pharmacy

Mysuru, India 570004

Email: bettaswamy25798@gmail.com

Abstract

Burn injuries disrupt the skin's natural barrier, making patients highly vulnerable to infections, which remain a leading cause of morbidity and mortality. The appropriate use of antibiotics is essential in preventing and managing burn wound infections. Topical antimicrobial agents, such as silver sulfadiazine and bacitracin, play a key role in reducing microbial colonization and promoting wound healing, although some agents may delay epithelialization. Systemic antibiotics, on the other hand, are not routinely recommended and should be reserved for cases with clinical evidence of infection, sepsis, or extensive burns. Current evidence indicates that prophylactic use of systemic antibiotics does not improve outcomes and may contribute to antimicrobial resistance. Emphasis is therefore placed on early wound care, hygiene, and careful monitoring for infection. This review highlights the indications, limitations, and evidence-based use of antibiotics in burn management, supporting a rational and judicious approach to therapy.

Key Words

Burn infection, topical antibiotics, systemic therapy, antimicrobial resistance, wound healing

Introduction

Burn injuries result in the loss of skin integrity, exposing underlying tissues to microbial invasion. Although burn wounds are initially sterile, colonization occurs rapidly within a few days, significantly increasing the risk of infection. Infection remains one of the leading causes of morbidity and mortality in burn patients.

This increased susceptibility is attributed to multiple factors, including disruption of the skin barrier, impaired local immune response, and the presence of necrotic tissue that provides a favourable environment for microbial growth.

Common pathogens associated with burn wound infections include *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Klebsiella* species.

Effective burn management focuses on preventing infection while promoting optimal wound healing. Antibiotics, particularly topical agents, play a central role; however, their use must be guided by clinical evidence to avoid complications such as antimicrobial resistance. This review aims to synthesize current evidence regarding the role of antibiotics in burn care.

Pathophysiology of Burn Wound Infection

Burn wounds undergo a dynamic process of microbial colonization that can progress to invasive infection if not adequately managed. The loss of the epidermal barrier facilitates microbial entry, while thermal injury impairs local immune defenses, including neutrophil function and cytokine response.

Additionally, the presence of devitalized tissue creates a nutrient-rich environment that supports bacterial proliferation. Over time, colonizing organisms may penetrate viable tissue, leading to systemic infection and sepsis if untreated. The progression from colonization to infection depends on factors such as burn depth, total body surface area involved, and host immune status.

Topical Antibiotics in Burn Management

Topical antimicrobial therapy is a cornerstone of burn care, primarily aimed at preventing microbial colonization and reducing infection risk.

Silver sulfadiazine remains one of the most commonly used agents due to its broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative organisms. It is particularly useful in partial-thickness and full-thickness burns. However, its clinical use is limited by delayed epithelialization and potential adverse effects such as leukopenia.

Bacitracin is frequently used in superficial burns and facial injuries due to its minimal toxicity and favourable safety profile. Unlike silver-based agents, it does not significantly impair wound healing, making it suitable for areas where rapid epithelialization is desired.

Overall, while topical agents are effective in controlling microbial load, their selection must be individualized based on burn severity, location, and patient factors.

Systemic Antibiotics in Burn Care

Systemic antibiotics should not be used routinely in burn patients. Their role is limited to specific clinical scenarios, including established infection, suspected sepsis, extensive burns involving more than 20% of total body surface area, and burns affecting high-risk anatomical regions.

Routine prophylactic use of systemic antibiotics has not demonstrated a reduction in infection rates. On the contrary, it contributes to the emergence of antimicrobial resistance and increases the risk of secondary infections. Therefore, systemic therapy should be guided by clinical findings and microbiological evidence whenever possible.

Evidence-Based Insights

Current literature consistently supports the selective use of antibiotics in burn care.

Silver-based dressings have been shown to reduce microbial colonization; however, they may delay wound healing in certain cases.

Studies evaluating systemic antibiotic prophylaxis have failed to demonstrate improved outcomes in uncomplicated burns. Instead, early wound debridement, proper hygiene, and meticulous wound care have been identified as more effective strategies for infection prevention.

These findings underscore the importance of prioritizing fundamental wound care practices over indiscriminate antibiotic use.

Current Guidelines

Guidelines from organizations such as the World Health Organization and the American Burn Association emphasize the judicious use of antibiotics in burn management. These recommendations advocate the use of topical antimicrobial agents while discouraging routine systemic antibiotic prophylaxis.

The focus is placed on early wound assessment, infection monitoring, and prompt initiation of targeted therapy when infection is confirmed. This approach aims to optimize patient outcomes while minimizing the risk of antimicrobial resistance.

Limitations and Challenges

Despite advances in burn care, several challenges remain in the optimal use of antibiotics. The emergence of multidrug-resistant organisms poses a significant threat to effective treatment.

Additionally, variability in clinical practice and lack of standardized protocols can lead to inappropriate antibiotic use.

Another limitation is the potential for topical agents to delay wound healing, which necessitates careful selection and monitoring. Further research is needed to develop newer antimicrobial strategies that balance efficacy with safety.

Conclusion

Topical antibiotics play a crucial role in preventing burn wound infections, whereas systemic antibiotics should be reserved for clearly defined clinical indications. Evidence strongly discourages routine prophylactic use of systemic antibiotics due to lack of benefit and risk of resistance.

Optimal burn management relies on a combination of early wound care, infection surveillance, and rational antibiotic use. Adherence to evidence-based guidelines is essential to improve clinical outcomes and address the growing challenge of antimicrobial resistance.

References

1. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. *Clin Microbiol Rev.* 2006;19(2)):403–434. DOI: 10.1128/CMR.19.2.403-434.2006

2. Atiyeh BS, Costagliola M, Hayek SN. Effect of silver on burn wound infection control and healing. *Burns.* 2007;33(2):139–148DOI: 10.1128/CMR.19.2.403-434.2006

3. Monafo WW. Topical therapy for burns. *Surg Clin North Am.* 1987;67(1) :133–

145. DOI: 10.1016/s0039-6109(16)44137-x

4. Wasiak J, Cleland H, Campbell F. Dressings for superficial and partial thickness burns. *Cochrane Database Syst Rev.* 2013;(3):CD002106.. DOI: 10.1002/14651858.CD002106.pub4

5. Vermeulen H, et al. Topical silver for treating infected wounds. *Cochrane Database Syst Rev.* 2007;(1):CD005486. . DOI: 10.1002/14651858.CD005486.pub2

6. American Burn Association. *Advanced Burn Life Support (ABLS) Provider Manual.* Chicago: American Burn Association; 2018.

7. Greenhalgh DG. Management of burns. *N Engl J Med.* 2019;380(24):2349–2359. doi:10.1056/NEJMra1807442

8. Singer AJ, Dagum AB. Current management of acute cutaneous wounds. *N Engl J Med.* 2008;359(10):1037–1046. doi:10.1056/NEJMra0707253

9. Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H. Topical silver for preventing wound infection. *Cochrane Database Syst Rev.* 2010;(3):CD006478. doi:10.1002/14651858.CD006478.pub2

10. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, et al. *Harrison's Principles of Internal Medicine.* 21st ed. New York: McGraw-Hill; 2022.

11. Williams NS, O'Connell PR, McCaskie AW, editors. *Bailey & Love's Short Practice of Surgery.* 28th ed. Boca Raton: CRC Press; 2022.

12. World Health Organization. *Burn management guidelines.* Geneva: WHO; 2018.